Findings from the active part of this trial and other large trials provided compelling evidence that SGLT2 inhibitors substantially slowed kidney disease progression and reduced cardiovascular risk.3–6 SGLT2 inhibitors also reduced risk of hospitalization for heart failure and acute kidney injury in patients with CKD and other high-risk conditions (including diabetes and heart failure).4 This evidence concerns the gene SLC5A2 and heart failure.